Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET exon 14 mutation + MET overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

›

over1year

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. (PubMed, BMC Cancer)

BPI-9016M showed manageable safety profile in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic NSCLC, but showed limited efficacy.

over 1 year ago

P1 data • PK/PD data • Clinical Trial,Phase I • Journal • Metastases

|

MET (MET proto-oncogene, receptor tyrosine kinase)

|

MET exon 14 mutation • MET overexpression • MET exon 14 mutation + MET overexpression

|

BPI-9016M